Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeWages, Salaries and Other
Others
Ratios

Design Therapeutics (DSGN) Shares Outstanding (Weighted Average) (2020 - 2021)

Design Therapeutics' Shares Outstanding (Weighted Average) history spans 2 years, with the latest figure at $55.2 million for Q3 2021.

  • For Q3 2021, Shares Outstanding (Weighted Average) rose 115.39% year-over-year to $55.2 million; the TTM value through Sep 2021 reached $55.2 million, up 115.39%, while the annual FY2020 figure was $15.8 million, N/A changed from the prior year.
  • Shares Outstanding (Weighted Average) for Q3 2021 was $55.2 million at Design Therapeutics, roughly flat from $55.1 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $55.2 million in Q3 2021 and bottomed at $15.7 million in Q1 2020.